Re-calculating the Cost of Coccidiosis in Chickens

reading time
Article | 02.10.2020

by Damer P. Blake, Jolene Knox, Ben Dehaeck, Ben Huntington, Thilak Rathiman, Venu Ravipati, Simeon Ayoade, Will Gilbert, Ayotunde O. Adebambo, Isa Danladi Jatau, Muthusamy Raman, Daniel Parker, Jonathan Rushton and Fiona M. Tomley.

Click here to download a PDF of the article as it appeared in the Veterinary Research Journal



Coccidiosis, caused by Eimeria species parasites, has long been recognised as an economically significant disease of chickens. As the global chicken population continues to grow, and its contribution to food security intensifies, it is increasingly important to assess the impact of diseases that compromise chicken productivity and welfare. In 1999, Williams published on of the most comprehensive estimates for the cost of coccidiosis in chickens, featuring a compartmentalised model for the costs of prophylaxis, treatment and losses, indicating a total cost in excess of £38 million in the United Kingdom (UK) in 1995.

In the 25 years since this analysis the global chicken population has doubled and systems of chicken meat and egg production have advanced through improved nutrition, husbandry and selective breeding of chickens, and wider use of anticoccidial vaccines. Using data from industry representatives including veterinarians, farmers, production and health experts, we have updated the Williams model and estimate that coccidiosis in chickens cost the UK £99.2 million in 2016 (range £73.0 - £125.5 million).

Applying the model to data from Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the United States resulted in estimates that, when extrapolated by geographical region, indicate a global cost of ~£10.4 billion at 2016 prices (£7.7 - £13.0 billion), equivalent to £0.16/chicken produced. 

Understanding the economic costs of livestock diseases can be advantageous, providing baselines to evaluate the impact of different husbandry systems and interventions. The updated cost of coccidiosis in chickens will inform debates on the value of chemoprophylaxis and development of novel anticoccidial vaccines.



Eimeria are protozoan parasites that can cause the enteric disease coccidiosis in all major livestock species. The consequences of infection include malabsorption, enteritis and, in severe cases for some Eimeria species, mortality, compromising economic productivity and animal welfare (Shirley et al., 2005). Chickens are the most economically important hosts; more than 68 billion were farmed in 2018, representing a third of all meat produced globally in addition to 1.38 trillion eggs for human consumption (FAOSTAT, 2020). 

Chicken production is expected to increase further in the next decade (Grace et al., 2012), highlighting the importance of pathogens that affect poultry to food security and the global agro-economy. Avian coccidiosis has previously been ranked in the top three diseases of poultry in the United Kingdom (UK) based on economic significance (Bennett and Ijpelaar, 2005), and in the top ten veterinary diseases based on impact on the poor in South Asia (Perry et al., 2002). 

In a 2019 survey of broiler veterinarians in the United States (US), coccidiosis (specifically Eimeria maxima) was ranked as the top disease-related issue in the opinion of respondents (USAHA, 2019). A similar survey of the US Association of Veterinarians in Egg Production (AVEP) indicated that coccidiosis was considered the most important disease or condition in replacement layers reared cage-free, and the second most important in those reared in cages (USAHA, 2019).

Several attempts have been made to quantify the consequences of coccidiosis in chickens. Eimeria life cycles have been modelled for several parasite species, assessing rates of replication and/or associated pathology (Parry et al., 1992; Henken et al., 1994a; Henken et al., 1994b; Klinkenberg and Heesterbeek, 2007; Johnston et al., 2001; Gilbert et al., submitted). The financial cost has been estimated for countries including Ethiopia, India, Romania and the UK (Bennett and Ijpelaar, 2005; Bera et al., 2010; Györke et al., 2016; Kinung'hi et al., 2004), with a model published by Williams being most comprehensive and most widely referenced (Williams, 1999).

In the latter study, the annual cost of coccidiosis in chickens was estimated to exceed £38 million in the UK at 1995 prices.  In the intervening period the UK chicken population has increased by 56% (1995-2018), with far larger expansions experienced in some other countries including Brazil, China and India, such that global chicken production is now double that of 25 years ago (FAOSTAT, 2020). During this time, the Williams 1995 figure of £38 million has been extrapolated to provide estimates of the global cost of coccidiosis in chickens beginning at US$ 0.8 billion in 2002 (Allen and Fetterer, 2002), growing to US$ 2.4 billion in 2005 and US$ 3 billion in 2006 (Dalloul and Lillehoj, 2006), all using the original figures from 1995. 

In the same period the value of the UK £ sterling (GBP) has changed such that £1 in 1995 was equivalent to £1.94 in 2019 (Bank of England, 2020). No further update has been published for the cost of coccidiosis in chickens and the calculation has not been repeated. 

Poultry production has undergone considerable development over the last 25 years. Broiler growth rates have increased, feed conversion ratios (FCR) fallen and average days to market reduced in intensive systems (Dierick et al., 2019). Similarly, egg production has changed including longer, more productive laying cycles (Bain et al., 2016). Poultry housing and management systems for intensively reared poultry have also evolved to improve health, welfare and productivity.

Approaches to control of coccidiosis have also changed. In the Williams model description of 1995, only broiler breeders were assumed to receive anticoccidial vaccination (Williams, 1999), whereas vaccination using formulations of live wide-type (non-attenuated) or attenuated vaccines is now the dominant form of anticoccidial prophylaxis for layer replacement, layer and broiler breeding stocks in much of the world (Elwinger et al., 2016).

Vaccination is not yet so common in broiler production, although public and legislative pressures are encouraging the search for cost-effective alternatives to anticoccidial drugs, especially in countries such as the US where (unlike the EU) ionophores are regulated as antibiotics. In response, 35-40% of US broiler companies have adopted annual cycles where two out of every six flocks receive anticoccidial vaccination instead of drugs (Chapman and Jeffers, 2014). More recently, it has been reported that more than 50% of US broilers are now raised antibiotic-free, indicating the absence of anticoccidial chemoprophylaxis (USAHA. 2019). In addition to vaccination as a replacement for chemoprophylaxis, bioshuttle programs using vaccination with a wild-type (non-attenuated) product followed by an anticoccidial drug is increasingly popular in countries such as the US. 

In this paper we describe the application of the Williams compartmentalised model to calculate the cost of coccidiosis in chickens using data collected in 2016 from countries representing six different continents, including updates to address recent changes in poultry husbandry and marketing. Understanding of the economic cost, or burden, or livestock diseases has evolved since the original publication (Williams, 1999, Rushton et al., 1999), recognising the contribution of indirect costs such as infrastructure and services as well as direct costs of control, mortality and morbidity. Thus, using the Williams model we have estimated the nominal financial cost of coccidiosis in chickens in 2016. 


Materials and methods

Data collection

A questionnaire was prepared to capture data required to complete the 'compartmentalised model for the estimation of the cost of coccidiosis' described previously by Williams (1999), including details of feed, drug and vaccine costs, health and performance parameters. The questionnaire was approved by the Social Science Research Ethical Review Board (SSRERB) of the Royal Veterinary College and assigned the reference URN SR2017-1248. Between three and ten industry representatives including veterinarians, farmers, integrators, poultry production and poultry health experts were surveyed in each of Brazil, Egypt, Guatemala, India, New Zealand, Nigeria, the United Kingdom (UK, including Great Britain and Northern Ireland) and the United States of America (US) between 2016 and 2017. 

Respondents were anonymised at the time of data collection. In the UK, additional data were collected, anonymised and amalgamated by the British Poultry Council (BPC), producing a dataset that was representative of British poultry producers and integrators. Where a range of figures was recorded, the mid-point was calculated. International poultry production figures were accessed using FAOSTAT (; FAOSTAT, 2020), recording figures for 2016 to align with data collected from poultry industry representatives. FAOSTAT was originally accessed in 2018, but figures were subsequently updated by FAO and revised here as of May 19th, 2020. Additional details were accessed from Eurostat (2020), accessed July 27th 2020, and from broiler and layer management guides using the editions that were valid in 2016-2017, as referenced where relevant.

Data analysis

The method developed by Williams (1999) was adopted, including a series of 12 compartmentalised components covering costs related to chick purchase and rearing, performance, anticoccidial prophylaxis and therapy in broiler, layer and breeder chickens (Table 1). Equations used without modification are summarised, with supporting data presented for all modifications. Figures used in analysis were updated from data recorded in the UK alone in 1995 to Brazil, Egypt, Guatemala, India, New Zealand, Nigeria, the UK and the US in 2016-2017. The countries included were selected to represent major poultry-producing region in South America, North Africa, Central America, Asia, Oceania, sub-Saharan Africa, Europe and North America, respectively. 

Table 1. Summary of compartments for estimation of the cost of coccidiosis (Williams, 1999) and modifications undertaken here

Prices, international currency and quantity calculations

The analysis used nominal prices from 2016. The currency exchange rates used in this study were set using Google Currency Converter on November 13th 2016. Rates against one (1) UK £ (sterling) were 0.22 Brazilian real, 0.719 Egyptian pounds, 0.012 India rupees, 0.48 New Zealand dollars, 0.0021 Nigerian naria, and 0.719 US dollars (also used in Guatemala). US tons were converted to metric tonnes where necessary using the conversion factor 0.907. Calculated costs are presented in millions to a maximum of five significant figures to assist clarity. 



The cost of anticoccidial prophylaxis for commercial broiler chickens

Figures for annual production of broiler chickens can be accessed by country or region using FAOSTAT, presented as tonnes of dressed meat (search criteria: Production / Livestock primary / Region / Production quantity / Meat, chicken) or number slaughtered for meat (search criteria: Production / Livestock primary / Region / Producing animals slaughtered / meat, chicken), recognising that both will include a small proportion of non-broiler derived meat (e.g. spent hens; Table 2).

Table 2. Values used to calculate the cost of anticoccidial prophylaxis in broiler and broiler breeder chickens.

Consideration of the Cobb and Aviagen broiler management manuals suggested that 74.3% of a broiler carcass can be used for meat (Aviagen, 2014; Cobb-Vantress, 2012), although the UK industry view was that 71% was more realistic, a marginal increased on the figure presented previously (Williams, 1999). Thus, figures for dressed meat produced can be used to estimate total live weight with a meat yield factor of 1.408 (Figures 1 and 2). For the UK, and other countries in the EU, accurate data regarding total live weight can be accessed directly with no need for these calculations using Eurostat (2020), indicating production of 1.79 million tonnes live weight in the UK in 2016 (Table 2). 

Figure 1. Meat yield factor equation
Figure 2. Liveweight equation

Calculating the cost of anticoccidial prophylaxis using the Williams model for 1995 assumed that all broiler chickens received ionophore or non-ionophore (chemical) drugs (Williams, 1999). By 2016, the situation was more complex. While the majority of broiler chickens continued to receive anticoccidial drugs in the UK, up to 3% of broilers may have been reared drug-free under organic or other systems (Editor, 2007). The use of live anticoccidial vaccines in chicken production has increased significantly since 1995. Anticoccidial vaccination remains uncommon in UK broiler production, but 35-40% of US broiler producers used anticoccidial vaccines instead of chemprophylaxis for at least two flocks per year by 2014 (Chapman and Jeffers, 2014). Here, for the UK calculation we assume that up to 3% of broiler chickens were vaccinated, and 97% of broilers received conventional chemoprophylaxis.

Anticoccidial prophylaxis for chickens using chemical or ionophore drugs is usually administered via the feed. Consideration of the feed conversion ratio (FCR) achieved during chicken production can be used to estimate total feed consumption. In the UK, our survey and the broiler management manuals suggested average FCR to have been 1.6 in 2016 (Aviagen, 2014; Cobb-Vantress, 2012), although variation in efficiencies of production would be expected to change FCR, suggesting that the average may vary between producers. Thus, if 1.79 million tonnes live weight chicken were produced in the UK in 2016, assuming an FCR of 1.6, the total quantity of chicken feed consumed would have been at least 2.87 million tonnes (Figure 3). 

Figure 3. Feed consumption equation

Referring to the questionnaire, in the UK it is common practice to add an additional 10% whole wheat to the formulated ration, although the precise figure is likely to vary as the price of wheat fluctuates. Thus, formulated feed represented ~90% of the chicken feed consumed, equivalent to 2.58 million tonnes in 2016. Ross 308, followed by Cobb 500 broiler chickens were the most popular lines used in the UK in 2016 so the Aviagen and Cobb broiler nutrition and performance supplements were considered for feed consumption parameters (Aviagen, 2014; Cobb-Vantress, 2015). The Aviagen figures indicate that ~6.2% of total feed would have been consumed as starter diet over the first 10 days for chicks on a 42 days program, rising to 8.9% on a 35 days program (Aviagen, 2014).

Here, we have assumed an intermediate 39 day program, indicating that 7.2% of the 2.58 million tonnes formulated feed would have been consumed as started diet (Table 2). While practices vary considerably between producers, assuming that a starter feed containing a chemical (i.e. non-ionophore), or more commonly a combination chemical + ionophore drug, was used at an average cost of £5.50 drug per tonne supplemented feed, the total cost of supplementation would have been £0.99 million for broilers on an intermediate 39 day program in 2016 (Table 2, range £0.85-£1.22 million for 35 to 42 days). 

Between 27.3% and 39.0% of feed is consumed as grower diets from days 11 to 22 on 42 and 35 days broiler programs, respectively, although many producers include additional switches during these periods. Ionophores are the most common anticoccidial drugs used in broiler production, representing 72.3% by weight of anticoccidial drugs sold in the UK in 2013, the last year that the Veterinary Medicines Directorate reported on ionophore use (UK-VARSS, 2014). 

Assuming that ionophore anticoccidial drugs were used in combination products for the first grower phase on a 39 days program, the total cost of supplementation would have been £4.37 million in 2016 based upon 31.8% of total feed consumed (Table 2, range £3.76-£5.37 million).

The majority of feed is consumed in the finisher phase, from day 23 onward, representing between 66.5% and 52.1% of formulated feed on 42 and 35 days programs, respectively (61.0% for 39 days). Ionophores are commonly fed alone during this period at an average cost of £3.50 per tonne supplemented feed. Withdrawal periods vary from 0 to 5 days, depending on the product used, and were estimated to represent 25% of the finisher phase without chemoprophylaxis, indicating a total cost of supplementation of £4.13 million in 2016 (range £3.53-£4.50 million). Thus, the total estimated cost of anticoccidial-supplementation in feed was £9.50 million for those broilers that received chemoprophylaxis in 2016 (range £9.11-£10.12 million). 

Figures from FAOSTAT report that 1.05 billion chickens were reared for meat in the UK in 2016 (search criteria: Production / Livestock primary / Region / Producing animals slaughtered / meat, chicken). Assuming that 97% received anticoccidial chemoprophylaxis, the cost for each UK broiler chicken treated would have been £0.01 in 2016. 

The cost of anticoccidial vaccination for broiler chickens is difficult to quantify, but based on our survey is approximately £0.03 per dose in the UK where live attenuated vaccines are licensed for use (Table 2). If 3% of the broiler chickens reared in 2016 were vaccinated, representing 31.5 million doses, the cost would have been £945,000. Thus, the total financial cost of prophylaxis for coccidiosis (anticoccidial drugs and vaccines) in the UK broiler sector is estimated to have been £10.44 million in 2016.

Using the same equations populated with data collected from surveys in Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US suggested that the annual costs of broiler prophylaxis using drugs of vaccines would have been £105.80, £3.70, £0.63, £5.78, £2.19, £1.67 and £130.10 million, respectively (Table 2). 

The costs of anticoccidial vaccination for broiler breeder chickens

As in 1995, broiler breeders are routinely vaccinated in the UK and much of the world against coccidiosis. In 1995 the percentage of broiler breeders used to produce commercial broiler progeny was estimated to have been at least 1.15% (Williams, 1999). In 2016 this figure had dropped to 0.77%, equivalent to 130 chicks produced per broiler breeder hen, suggesting that 8.08 million breeding chickens would have been required to produce the 1.05 billion broilers reported from the UK in 2016. The average cost of anticoccidial vaccination per broiler breeder in the UK in 2016 was £0/08, unchanged from 1995, suggesting an annual cost of £0.65 million (Table 2). 

Equivalent figures for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US would have been £0.59, £0.21, £0.005. £0.56, £0.08, £0.06 and £0.335 million, respectively, taking into account the variable costs per dose of the live wild-type or attenuated vaccines licensed for use in some of these countries. Vaccines used in Guatemala was provided from the US market, commonly delivered to chicks produced in the US and shipped to Guatemala. 

The cost of anticoccidial therapy for broilers and broiler breeders

The true occurrence of coccidiosis in broiler and broiler breeder stock is often poorly documented, representing commercially sensitive information. In the UK, the consensus opinion was that the occurrence of disease outbreaks was <5% across all flocks, where assessment of 'occurrence' is usually based on gross pathology. Laboratory confirmation is less common. Here, we have used figures of 3% for broiler flocks, and 2% for broiler breeders (Table 3). The cost of therapeutic treatment per chicken was estimated to be £0.02 for broiler and broiler breeders. 

Table 3. Values used to calculate the cost of anticoccidial therapy in broiler and broiler breeder chickens

When broiler and broiler breeder chickens are treated for coccidiosis, therapy is administered to the entire house/pen, suggesting that 31.5 million broilers and 161,538 broiler breeders received treatment for coccidiosis in the UK in 2016 (Figure 4, Table 3). Thus, the total cost of treatment for coccidiosis in the UK in 2016 was estimated to be £0.63 million for broilers, and £0.003 million for broiler breeders, although the true figures are likely to vary according to the actual occurrence of coccidiosis. 

Figure 4. Cost of therapy equation

Application of the same equation to costs in Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US revealed considerable variation, underpinned by notably different estimates for the occurrence of coccidiosis from 5% to 80% for broilers, and 2% to 80% for broiler breeders (Table 3).


The cost of broiler mortality caused by coccidiosis

Our survey suggested that approximately 2% of UK broilers would be expected to die or (more commonly) be culled in a house affected by coccidiosis (Table 4). Thus, if 31.5 million broilers were in houses affected by coccidiosis, mortality would have been 630,000 (Figure 5). Note, the figure does not included losses due to subsequent mortality caused by other opportunistic pathogens. 

Figure 5. Mortality due to coccidiosis equation

Losses attributed to mortality were divided in the Williams model into the chicken value, including cost of purchase (Figure 6), and the revenue that had been lost when chickens were not sold minus the rearing costs that were saved due to premature mortality (Figure 7; Williams, 1999). In total 630,000 broilers were estimated to have died due to coccidiosis in the UK in 2016 (as above). In the model, chick value was calculated at an average time point of 3 weeks of age, representing the beginning of the period when mortality is most likely to occur (Williams, 1998)From our survey, each individual broiler would be worth on average £0.80 at 3 weeks of age, indicating a total cost of £0.50 million (Figure 6). The average live weight for a commercial broiler in the UK at the time of slaughter in 2016 was 2.191 kg (Cobb-Vantress, 2012). 

Figure 6. Value of chickens lost due to coccidiosis equation
Figure 7. Net loss equation

From our survey, an average of £0.80 was paid per kg at the time of slaughter, indicating a loss of £1.75 per individual, balanced by a reduction in rearing costs of £1.12 per chicken lost, resulting in a net loss of £0.63 per chicken or £0.40 million in total (Figure 7). Thus, the total cost of broiler mortality in the UK in 2016 was £0.90 million. The equivalent costs for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US would have been £78.52, £27.96, £0.96, £35.92, £1.14, £17.73 and £54.45 million, respectively (Table 4).

Assuming a lower level of mortality in broiler breeder flocks given that most will have been vaccinated, the number of broiler breeders lost due to coccidiosis per annum would have been relatively small. The cost of broiler breeder loss was not calculated in the original Williams model for this reason, and because the actual cost of breeding stock is very difficult to define.

The cost of morbidity: reduced broiler weight gain due to coccidiosis

Eimeria are ubiquitous and it is likely that most broiler chickens are exposed to one or more Eimeria species during their lives (Clark et al., 2016). While severe coccidiosis can result in mortality, morbidity is far more common with both malabsorptive and haemorrhagic enteric disease compromising nutrient absorption and body weight gain (Sakkas et al., 2018). In the original model the average effect of coccidiosis was estimated to reduce final body weight by 0.1 kg when compared to an unexposed equivalent, although 0.05 kg was used as a conservative estimate (Williams, 1999). Consideration of more recent studies with malabsorptive Eimeria species such as E. acervulina and E. maxima suggest a greater impact, with reductions in excess of 0.1 kg (Sakkas et al., 2018; Rochell et al., 2016), although the consequences of infection with less pathogenic species such as E. mitis and E. praecox are less clear. In line with these data, and recognition of increased growth rate in modern broiler chickens and hence greater likely impact of infection, our conservative estimate of final reduction in live body weight as a consequence of Eimeria infection was raised to 0.07 kg (Table 4). 

Thus, with 1.05 billion broiler chickens produced in the UK in 2016, the predicted total loss of body weight caused by Eimeria infection would have been 73,500,000 kg. Given the value of 0.80 per kg body weight at slaughter (as above), the loss would have equated to a total of £58.80 million (Figure 8; Table 4). 

Figure 8. Cost of reduced weight gain equation

Changing the estimated reduction in live body weight by ±0.02 kg resulted in a 28.6% increase/decrease in total cost (between £42.00 and £75.60 million). The equivalent costs of a 0.07 kg reduction in broiler body weight gain for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US would have been £512.78, £54.22, £5.17, £334.26, £7.39, £29.82 and £687.43 million, respectively. 

The cost of morbidity: higher feed conversion ratio (FCR) due to coccidiosis

In addition to lower final body weight, reduced nutrient absorption as a consequence of coccidiosis will also be reflected by a higher feed conversion ratio (FCR). A higher FCR illustrates the requirement for greater feed intake to achieve the same body weight gain due to inefficiencies in diet utilisation and in additional nutrition partition to repair damaged enteric tissues and the birds immune response. The influence of Eimeria infection on FCR is difficult to define. A wide range of variation has been reported, often following significant parasite challenge that might exceed common levels of challenge in the field. In the original model, Williams considered the effect of Eimeria infection on FCR to be an increase of 0.1, using 0.05 as a conservative measure. We have used the same figures here (Table 4). 

From our survey, broiler diets commonly include 10% wheat at an average cost of £160 per tonne in the UK in 2016, although wheat prices can vary significantly resulting in notable variation over time. Formulated feed, commonly representing 90% of the total diet, cost on average £275 per tonne (Table 4). Combined, the mean feed price can be calculated using the equation in Figure 9 to be £263.50 per tonne in the UK in 2016. Thus, using the figures for broiler live weight produced per annum described above, a predicted FCR increase of 0.05, and a mean feed price of £263.50 per tonne, the total cost of increased FCR due to coccidiosis was £23.60 (Figure 10). 

Figure 9. Mean feed price equation
Figure 10. Cost of increased FCR equation

Changing the estimated increase in FCR by ±0.02 resulted in a 40.0% increase/decrease in total cost (between £14.16 and £33.03 million). Feed costs and ratios for formulated: non-formulated feed use varied between countries (Table 4), resulting in total costs of £241.40, £16.88, £5.95, £66.26, £4.42, £4.03 and £273.89 million for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US, respectively, when using a increased FCR of 0.05.

The cost of morbidity: lower broiler breeder egg production

In the UK in 2016, we already estimated 161,538 broiler breeder chickens would have been affected by coccidiosis. A sex ratio of one male per ten females has been described for modern broiler breeder chickens (Pizzari, 2017), suggesting that 146,853 broiler breeder hens were used. The effect of Eimeria infection on egg production is not clear. The Williams model took a conservative approach, suggesting the loss of one egg per hen, per year. An additional parameter not considered in the original model is hatchability. While one egg may have been lost per hen, per year, only 85% might have been expected to yield a chick (Abudabos, 2010). 

From our survey, the average cost for a day old broiler chick in the UK was £0.33, suggesting a total loss of £0.04 million. The equivalent costs for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US were £0.84, £0.29, £0.28, £0.10, £0.18, £0.23 and £1.22 million, respectively (Table 4), with the differences reflecting different levels of coccidiosis reported in broiler breeder flocks from different countries. 

The cost of anticoccidial prophylaxis for commercial layer chicken replacements

The number of layers reared in the UK each year can be estimated using FAOSTAT (search criteria: Production / Livestock primary / Region / Producing animals slaughtered / eggs, hen, in shell), indicating that 53,489,000 hens were reared in total. In the Williams model, it was important to differentiate between replacement hens kept in cages or on litter, since different anticoccidial prophylaxis programs were used. However, comparison of management guides for chickens reared in enriched cages or on the floor indicate that both now follow step-down programs (Hy-Line, 2016a; Hy-Line, 2016b). Figures released by the Royal Society for the Prevention of Cruelty to Animals (RSPCA) suggest that 48% were accommodated as laying stock in enriched cages, with 1% in barn systems and 51% free range, of which 2% were organic (RSPCA, 2020; Table 5). 

Table 5. Values used to calculate the cost of prophylaxis and therapy in layer and layer-breeder chickens

In the original Williams model the use of vaccination in anticoccidial prophylaxis for layer chickens was not considered, reporting 100% chemoprophylaxis (Williams, 1999). By 2016, the situation had changed significantly, with at least 95% of layer chickens receiving live anticoccidial vaccination in the UK. From our survey, the average cost of an anticoccidial vaccine was 8p per dose in the UK in 2016 (Table 5). Thus, if 95% of laying hens received vaccines, the total cost would have been £4.06 million. 

Comparison of management guides for rearing commercial layer chickens in caged or alternative systems in the UK suggested that stock reared using anticoccidial chemoprophylaxis usually follow step-down approaches divided into two or three different phases (Hy-Line, 2016a; Hy-Line, 2016b). Most commonly, ionophores were included at 100% or the optimal recommended rate from 0 to 6 weeks, or 0 to 3 and 4 to 6 weeks of age, respectively, followed by a final phase with ionophore at the minimum registered inclusion rate for 7-12 weeks (Williams, 1999).

The management guide suggests consumption of 0.40 kg, 0.71 kg, and 2.22 kg feed during each phase of the three step system, respectively (Hy-Line, 2016b; Table 5). Using the cost of £3.50 per tonne for ionophore supplementation at 100% of the recommended rate (as described above), the total cost of anticoccidial chemoprophylaxis for replacement layer hens in the UK in 2016 was £0.03 million. 

When the costs of prophylaxis for replacement layer chickens using drugs and vaccines are combined the total cost in 2016 in the UK would have been £4.09 million. Using the figures collected from our surveys in Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US the total cost of prophylaxis for replacement layer hens was £3.87, £0.38, £0.10, £2.53, £0.34, £1.15 and £1.82 million, respectively, in 2016 (Table 5). 

The cost of anticoccidial prophylaxis for layer breeder chickens

The majority of layer breeder chickens are now routinely vaccinated in the UK, and much of the world, to control coccidiosis. Assuming that the ratio of layer breeders to commercial layer progeny remained comparable to that used for 1995 (1.21%, Table 5), 647,217 layer breeder chickens would have been required in the UK in 2016. The average cost of anticoccidial vaccination per layer breeder in the UK in 2016 was 8p. Assuming a ratio of vaccination to chemoprophylaxis comparable to that used for replacement layers, the total annual cost of layer breeder prophylaxis would have been £0.05 million in the UK (Table 5). Equivalent figures for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US would have been £0.05, £0.005, £0.001, £0.11, £0.004, £0.02 and £0.02 million, respectively, again influenced by a far lower vaccine cost per dose in the US. 

The cost of anticoccidial therapy for layer and layer breeder chickens

Based upon the figures shown above, 27,814,280 layer and 647,217 layer breeder chickens may have been floor-raised in the UK in 2016. If ~4% of flocks required treatment for coccidiosis at a cost of 2p per individual (Table 5), the total cost would have been £0.02 and £0.0005, respectively (using the equation in Figure 4). When considering costs for Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US the figures demonstrated notable variation, reflecting differences in the occurrence of coccidiosis and the costs of therapy (Table 5). 

The financial cost of coccidiosis in chickens

Combined, the 12 compartments previously described in the Williams model have been used to estimate the cost of coccidiosis in the UK (Williams, 1999). Repeating the analysis using figures for the UK updated to 2016 suggest a combined total nominal financial cost of £99.23 million per annum; a 2.6-fold increase from the last calculation in 1995. 

Considerable interest exists in calculating the global cost of coccidiosis in chickens. Extrapolation of any sort is hazardous and will certainly be inaccurate, failing to adapt to regional variation in consumer preferences, markets, environments, husbandry and biosecurity. In an effort to reduce such inaccuracies we have also calculated the total cost of coccidiosis using an updated version of the Williams model for Brazil, Egypt, India, Guatemala, New Zealand, Nigeria and the US, each representing a different continent or distinct region, and presenting a different continent or distinct region, and presenting a range of costs between £16.34 and £1175.88 million (Table 6). 

Table 6. The total cost of coccidiosis calculated per country and extrapolated per region

Taking these countries as exemplars, the total cost of coccidiosis in chickens in 2016 per continent or region was shown to vary between "112.39 and £5181.97 million (Table 6), resulting in a global estimated total cost of £10,362.03 in 2016. Adjusting the estimates used for weight gain lost during infection and FCR increase as a consequence of infection by ±0.02 in each country resulted in between 17.3% and 26.4% variation (Table 6). Thus, the range for the global cost of coccidiosis was estimated to fall between £7711.51 and £13,012.54 million per annum. Based upon the number of chickens slaughtered and the total calculated cost, the average cost of coccidiosis per chicken produced was £0.16.

Partition of the financial cost calculated for each country into costs associated with control (drugs for prophylaxis, vaccines), mortality or morbidity revealed notable variation (Table 7). The contribution to cost attributed to control was greatest in Guatemala (44.6%) and lowest in India (2.4%). Costs associated with mortality were proportionately highest in Nigeria (30.2%) and Egypt (26.2%), lowest in the UK (0.9%). The costs of morbidity were most important, representing more than 80% of the total financial cost in India, the UK and the US (Table 7). 

Table 7. The contribution of costs for control, mortality and morbidity to the cost of coccidiosis (millions)



Understanding the financial cost of diseases that compromise animal production and welfare is important, providing a baseline for comparison of husbandry systems, risk factors and interventions (Rushton et al., 2018). Eimeria are the most economically significant parasites of poultry but their true cost to producers remains unclear. In 1995, the cost of coccidiosis to UK chicken production was estimated to be £38.59 million, of which 98.1% was attributed to the broiler sector. Recalculating the figure using prices from 2016, including costs associated with vaccination, indicate a financial cost of £99.23 million per annum, 95.1% of which derived from broiler production. The notable increase in cost can be explained in part by the larger chicken population and currency inflation, although costs associated with broiler prophylaxis and impacts on growth (reduced weight gain and increased FCR) were notably higher, likely amplified by the considerable genetic progress achieved by the primary breeding companies in selection for faster growing and more feed-efficient broiler stock (Dierick et al., 2019). 

The increased cost of coccidiosis may also have been influenced by the withdrawal of antibiotic growth promoters (AGPs) from chicken diets. The impact of coccidiosis on gut integrity can be more severe in chickens that are not receiving AGPs as the damage caused by coccidiosis provides substrates for the replication of certain bacteria, disrupting the balance of the intestinal microbiome (MacDonald et al., 2017; MacDonald et al., 2019), potentially exacerbating malabsorption and enteritis, decreasing growth rates and increasing FCR.

The number of chickens estimated to be affected by coccidiosis was also notably higher than the figures used by Bennett and Ijpelaar, who predicted in 2005 a range of costs in the UK between £10.2 and £14.2 million per annum (Bennett and Ijpelaar et al., 2005). The percentage of broiler chickens lost due to coccidiosis was notably higher in every country surveyed in 2016 than the UK in 1995, possibly representing an underestimate in the original model (Williams, 1999).

Costs attributed to coccidiosis in layer replacements in the UK remained a small proportion of the total (4.15% of the total costs in 2016), but represented a 37-fold increase from 1995. The increase was primarily due to greater costs of prophylaxis, reflecting the switch from chemoprophylaxis to vaccination driven in part by the BEIC Lion code that forbids the use of in-feed anticoccidials from the age of 12 weeks in replacement layers (BEIC, 2013). Additionally, the use of relatively expensive live attenuated anticoccidial vaccines in the UK that include most or all Eimeria species will have increased the cost further. It is worth noting that levels of vaccination in replacement layer stock may vary between countries. The increase was replicated in layer breeding stock.

Application of the updated model to data collected from surveys in Brazil, Egypt, Guatemala, India, New Zealand, Nigeria and the US revealed considerable variation in the costs of production, the occurrence of infection and the outcomes of disease. The occurrence of coccidiosis was considered to be far higher in Egypt, Guatemala, New Zealand and Nigeria than the other countries surveyed, directly contribution to increased costs for treatment and mortality. The visible consequences of clinical coccidiosis were lower in Brazil, India, the UK and the US, where costs associated with morbidity were proportionately higher. The balance between losses incurred due to coccidiosis and the costs of prevention may reflect country-specific access to best practice technologies and chicken lines that are best adapted to their environment(s). Variation in the ongoing development of capacity and practice in each country is likely to have contributed to the differences reported in mortality and is not directly captured in this model.

The prices of feed, and especially vaccine doses, were far lower in the US than any of the other countries, limiting the costs of prophylaxis per layer and broiler/layer breeder, and the consequences of increased FCR. Countries such as the US routinely use non-attenuated anticoccidial vaccines with a greater productivity capacity, and thus lower cost, than the attenuated vaccines licenced for use in the EU. It is worth noting that bioshuttle programs, including use of a non-attenuated live vaccine followed by an anticoccidial drug, are increasingly popular in countries such as the US, incurring increased costs due to tandem prophylaxis and suggesting that figures for the US are an underestimate.

The cost of coccidiosis in chickens in India has previously been estimated to be 1.14 billion Indian rupees (INR) in 2003-2004 (Bera et al., 2010), equivalent to £17 million, based upon a historic conversion rate of £1: INR 67 (Currency Converter, 2020). The figure represented here is far higher, in part reflecting the rapid expansion of poultry production in the region (Grace et al., 2012), but perhaps also a more comprehensive model. Previous figures for the other countries assessed were not available to be compared.

Flock-level analyses have been reported from Ethiopia and Romania, identifying costs of 898.80-5301.80 Ethiopian Birr per farm, or 0.55 and 0.53 Birr per chicken in small and large scall farms, respectively, in Ethiopia (Kinung'hi et al., 2004), and of EU€3162.4 per flock in Romania in 2010 (Györke et al., 2016). Fornace and colleagues assessed the impact of individual Eimeria species occurrence on the viability of smaller broiler farms in Ghana, Tanzania and Zambia, calculating farm gross economic margins and identifying reductions associated with more pathogenic species (Fornace et al., 2013). The impact of subclinical Eimeria infection has been investigated in Norway, where the authors identified a significant impact but did not discuss costs (Haug et al., 2008). 

Figures used to define the 'global cost' of coccidiosis in chickens have been cited widely and have varied enormously (Shirley et al., 2005; Allen and Fetterer, 2002; Dalloul and Lillehoj, 2006). We have estimated the financial cost for eight key countries, across six continents, which are defined by a significant contribution to chicken production in their region. Brazil and the US, selected to represent South and North America, are among the world's biggest producers of poultry. Egypt and Nigeria, chosen to represent North and sub-Saharan Africa, lead production within their respective regions. India is host to one of the biggest expansions in poultry production in the world (Grace et al., 2012). Guatemala and New Zealand were pragmatic selections based on availability of data. 

While production levels are far lower in the latter countries, they are representative of their wider regions. Using data from these countries and the UK, representing Europe, we have estimated the total financial cost of coccidiosis in chickens per region in an effort to reduce variation. It is important to note that the figures are far from comprehensive and doubtless miss regional variation from other countries. Nonetheless, extrapolating by continent or region, rather than from a single country, does serve to reduce gross variation and strengthen a tentative estimate of the global cost of coccidiosis in chickens. It is important to note that this estimate remains based on a model that relies on many assumptions. As such, the figure of ~£10.36 billion, or £0.16 per chicken produced, can only be considered to be a guide. Variation of important parameters such as body weight gain lost in kg and FCR (both ±0.02) produced a range of estimates from £7.71 to £13.01 billion per annum.

Variation in other parameters would expand the range further. The model does not take an entirely holistic view, omitting details such as electricity and water, or depreciation of facilities and equipment, all of which may serve to increase the true economic cost. Similarly, the model does not include the consequences of gut dysbiosis caused by coccidial infection. Eimeria infection has been shown to modify enteric bacterial population structures with significant variation in commensal genera such as Bacteroides and Lactobacillus (MacDonald et al., 2017; Chen et al., 2020). Variation in microbiome composition has been associated with higher or lower FCR (Singh et al., 2014), potentially exacerbating the two biggest components of the cost of coccidiosis (reduced weight gain and increased FCR). 

Eimeria infection has also been associated with increased pathogen carriage. Concurrent E. tenella infection can increase intestinal Campylobacter jejuni and Salmonella enterica Typhimurium load (MacDonald et al., 2019; Arakawa et al., 1981). Most importantly, Eimeria co-infection is a major contributory factor to necrotic enteritis (NE) caused by Clostridium perfringens (Moore, 2016). The global cost of NE has been estimated to exceed US$6 billion (Wade and Keybrun, 2015), adding considerable extra indirect expense to the direct cost of coccidiosis in chickens.

The influence of gut dysbiosis due to Eimeria infection on litter quality has also not been included. Wet litter resulting from dysbiosis is a notable risk factor for pododermatitis, a leading cause of ill health, culling, condemnation and quality downgrades (de Jong et al., 2014). Pododermatitis is also used as a welfare indicator; its occurrence can result in reputational damage to a producer/integrator. Practically, wet litter caused by dysbiosis can incur extra costs associated with additional bedding, labour and electricity for extraction fans and heating to remove moisture.

In the future, understanding the broader contribution of Eimeria infection and coccidiosis to overall health burdens in chickens will underpin improved estimates of true economic cost beyond the absolute figures provided here. Projects such as the Global Burden of Animal Diseases (GBADs) aim to explore this topic, establishing baseline figures for production of livestock in the absence of pathogens and defining the consequences of infection (Rushton et al., 2018).

The most significant addition required to update the Williams model to calculate the cost of coccidiosis in chickens related to the far wider use of live anticoccidial vaccines. Anticoccidial vaccines have become the dominant form of anticoccidial prophylaxis in layer and breeding stock around much of the world (Elwinger et al., 2016), with burgeoning interest in "no antibiotics ever" food production expected to increase vaccine use further. It has been suggested that more than 40% of US broiler producers now use anticoccidial vaccines in at least one flock each year (Polansek, 2018), supported by statistics from a leading industry benchmark that more than 30% of commercial broilers sold in the US since 2016 have received an anticoccidial vaccine (personal communication).

Expanding the use of live vaccines further has been limited by production capacity, especially for the less productive attenuated vaccines used in the EU (Blake et al., 2017). The possible future emergence of recombinant or vectored anticoccidial vaccines would require further amendments to the model and could significantly influence the economics of chicken production. 

In conclusion, the global cost of coccidiosis in chickens is estimated to have been ~£10.36 billion in 2016, including losses during production and costs for prophylaxis and treatment. As the human population continues to expand and the challenge to achieve food security increases (Grace et al., 2012), improving understanding and control of economically significant pathogens of livestock remains essential. 


References are available on request. 


This article originally appeared in Veterinary Research (
global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us


Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.

To view all products and services, select Global from the dropdown menu or click .




North America


South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.


United States

Click here to visit the local website or close this popup to stay on the global website.

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now